Search Results

You are looking at 31 - 40 of 47 items for :

  • "Interferon-α" x
  • Refine by Access: All x
Clear All
Full access

Tumor Mutation Burden and Depression in Lung Cancer: Association With Inflammation

Daniel C. McFarland, Devika R. Jutagir, Andrew H. Miller, William Breitbart, Christian Nelson, and Barry Rosenfeld

interferon-α. 24 , 25 Likewise, animal research has supported this association through the induction of a sickness-like state that mimics depression after the administration of lipopolysaccharide, 8 , 24 – 26 an endotoxin that induces inflammation. In

Full access

The Role of Autologous and Allogeneic Hematopoietic Stem Cell Transplantation for Hodgkin Lymphoma

Leona Holmberg and David G. Maloney

benefit with IL-2 and interferon-α immunotherapy after ASCT in patients with NHL, but saw no benefit in patients with HL. The use of cloned autologous or allogeneic T cells for treating HL is in its infancy and also has been hampered by lack of tumor

Full access

Optimization of Postremission Therapy in Follicular Lymphoma: Efficacy of Rituximab Maintenance

Rupali Roy and Leo I. Gordon

interferon-α alone or in combination, but no long-term benefits have been observed in terms of overall survival, and in many cases toxicity has been significant. 29 – 31 Radioimmunotherapy has been used as an adjunct with reasonable tolerability. The phase

Full access

Why, When, and How to Prevent Hepatitis B Virus Reactivation in Cancer Patients Undergoing Chemotherapy

Bhumsuk Keam, Jeong-Hoon Lee, Seock-Ah Im, and Jung-Hwan Yoon

rate. Interferon-α should be avoided in view of the bone marrow suppressive effect and the risk of hepatitis flares. 27 Figure 2 Proposed practical algorithm for the prevention of HBV reactivation in patients with cancer undergoing chemotherapy

Full access

NCCN Task Force Report: Tyrosine Kinase Inhibitor Therapy Selection in the Management of Patients With Chronic Myelogenous Leukemia

Susan O'Brien, Ellin Berman, Joseph O. Moore, Javier Pinilla-Ibarz, Jerald P. Radich, Paul J. Shami, B. Douglas Smith, David S. Snyder, Hema M. Sundar, Moshe Talpaz, and Meir Wetzler

randomized 1106 patients to undergo initial therapy with either imatinib, 400 mg daily, or interferon-α plus low-dose cytarabine. At 8-year follow-up, 55% of patients remained on imatinib, and the estimated rates of event-free survival, freedom from

Full access

Histiocytic Neoplasms, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology

Ronald S. Go, Eric Jacobsen, Robert Baiocchi, Ilia Buhtoiarov, Erin B. Butler, Patrick K. Campbell, Don W. Coulter, Eli Diamond, Aron Flagg, Aaron M. Goodman, Gaurav Goyal, Dita Gratzinger, Paul C. Hendrie, Meghan Higman, Michael D. Hogarty, Filip Janku, Reem Karmali, David Morgan, Anne C. Raldow, Alexandra Stefanovic, Srinivas K. Tantravahi, Kelly Walkovich, Ling Zhang, Mary Anne Bergman, and Susan D. Darlow

-Chester disease . Neurol Clin Pract 2018 ; 8 : 15 – 20 . 29517068 10.1212/CPJ.0000000000000422 100. Arnaud L , Hervier B , Néel A , CNS involvement and treatment with interferon-α are independent prognostic factors in Erdheim

Full access

Current Issues in Chronic Myeloid Leukemia: Monitoring, Resistance, and Functional Cure

Jorge Cortes, John M. Goldman, and Timothy Hughes

. 68 Hehlmann R Lauseker M Jung-Munkwitz S . Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia . J Clin Oncol 2011 ; 29 : 1634 – 1642 . 69 Cortes J

Full access

Role of Immunotherapy in Triple-Negative Breast Cancer

Tanya E. Keenan and Sara M. Tolaney

cells to release interferon-α and mature into antigen-presenting cells, thereby increasing CD8+ T-cell infiltration in tumors. 55 The I-SPY 2 trial (NCT01042379) is currently investigating the estimated pCR impact of neoadjuvant SD-101 and pembrolizumab

Full access

Adult Intradural Primary Spinal Cord Tumors

Kamran Aghayev, Frank Vrionis, and Marc C. Chamberlain

, interferon-α, PTK787, or sunitinib. 112 – 123 However, no data exist on use of these agents for spinal meningiomas. Follow-up usually requires serial postoperative MRI and neurologic monitoring. Patients with no evidence of recurrence can be followed up

Full access

Kidney Cancer

Robert J. Motzer, Neeraj Agarwal, Clair Beard, Sam Bhayani, Graeme B. Bolger, Michael A. Carducci, Sam S. Chang, Toni K. Choueiri, Steven L. Hancock, Gary R. Hudes, Eric Jonasch, David Josephson, Timothy M. Kuzel, Ellis G. Levine, Daniel W. Lin, Kim A. Margolin, M. Dror Michaelson, Thomas Olencki, Roberto Pili, Thomas W. Ratliff, Bruce G. Redman, Cary N. Robertson, Charles J. Ryan, Joel Sheinfeld, Philippe E. Spiess, Jue Wang, and Richard B. Wilder

resection of their tumor. No systemic therapy has yet been shown to reduce the likelihood of relapse. Randomized trials comparing adjuvant interferon-α (IFN-α) or high-dose interleukin (IL-2) with observation alone in patients who had locally advanced